[](http://brain-mets.com/)

* [Friday October 6th](http://brain-mets.com/2641-program-2017/224-friday-october-6th-2017)

**08.30**

**Welcome coffee**

**08.45**

**Welcome address, Philippe Métellus (FR)**

**09.00**

**Diagnostic approaches**

**Chair: A. Carpentier (FR) & M. Smits (NL)**

* **09.00** Molecular profiling to allocate patients to targeted clinical trials,*J. M. Kros (NL)*
* **09.20** Brain Metastases,*M. Westphal (DE)*
* **09.40** Leptomeningeal Metastases, *E. Le Rhun (FR)*

**10.00**

**Immuno-oncology in CNS Metastases / Chair: F. A. S. Berghoff (AUT) & Dhermain (FR)**

* **10.00** Lessons from animal models, *M. Valiente (SP)*
* **10.20** Overview: immunotherapy in CNS Metastases, *M. Ahluwalia (US)*
* **10.40** Toxicity of immunotherapy in CNS Metastases, *A. Carpentier (FR)*

**11.00**

**Coffee break and visit of the exhibition**

**11.20**

**Combined treatments for CNS Metastases / Chair: E. Moyal (FR) & Z. Ram (IS)**

* **11.20** Combination of immunotherapy and radiotherapy, *F. Dhermain (FR)*
* **11.40** Combination of immunotherapy and other systemic pharmacotherapy, *G. Finocchiaro (IT)*
* **12.00** Combination of other systemic pharmacotherapy and radiotherapy, *U. Herrlinger (DE)*

**12.20**

**Keynote lecture / Chair: A. Carpentier (FR) & U. Herrlinger (DE)**

* **12.20** The future of radiotherapy for CNS Metastases: farewell to WBRT?*A. Chalmers (UK)*

**12.50**

**Lunch**

**14.00**

**Comprehensive care of patients with Brain Metastases**

**Chair: G. Finocchiaro (IT) & E. Le Rhun (FR)**

* **14.00** Epilepsy in CNS Metastases: primary and secondary prevention,*R. Rudà (IT)*
* **14.20** Maintaining cognitive function in patients with CNS Metastases receiving multimodality treatment, *J-S.Wefel (US)*
* **14.40** Prevention and treatment of cerebro-vascular complications, *C. Marosi (AUT)*
* **15.00** Efficacy, tolerability and safety of steroids in patients with CNS Metastases, *P. Roth (CH)*

**15.20**

**Interactive case reports (progression/criteria of evaluation)**

**Chairs: P. Métellus (FR) & M. Weller (CH)**

* **15.20** Case 1 (Syst chemo), *A. Darlix (FR)*
* **15.30** Case 2 (Immuno), *A. S. Berghoff (AUT)*
* **15.40** Case 3 (RT), *A. Modesto (FR)*

**15.50**

**Coffee break and visit of the exhibition**

**16.20**

**Keynote lecture / Chairs: M. Ahluwalia (US) & M. Westphal (DE)**

* **16.20** Assessing response and clinical benefit in clinical trials enrolling patients with Brain and leptomeningeal Metastases, *M. Weller (CH)*
* **17.00** Activities of EORTC BTG CNS Metastases Committee, *E. Le Rhun (FR)*
* **17.15** Guided poster walks

**20.00**

**Gala dinner**

* [Saturday October 7th](http://brain-mets.com/2642-program-d2-2017/225-saturday-october-7th-2017)

**08.00**

**Welcome coffee**

**08.30**

**Selected oral presentations / Chair: A. Chalmers (UK) & A. Tallet (FR)**

**10.10**

**Coffee break and visit of the exhibition**

**10.30**

**Highlights 2016-2017**

**Chair: R. Soffietti (IT) & C. Watts (UK)**

* **10.30** Basic research, *A. Boire (US)*
* **10.50** Neuropathology, *P. Wesseling (NL)*
* **11.10** Imaging, *M. Smits (NL)*
* **11.30** Surgery, *P. Métellus (FR)*
* **11.50** Radiation therapy, *E. Moyal (FR)*
* **12.10** Perspectives in systemic treatments for BM, *M. J. Van den Bent (NL)*

**12.30**

**Awards – Best communication and poster – Conclusions**

**12.45**

**Lunch**